Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, patient investors could find opportunity as the stock falls.

The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 87 cents per share. The maker of engineered products for the aerospace and other industries posted ...

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...